Purpose of Review

Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide. Although screening and early treatment guidelines for DR have significantly reduced the disease burden, restrictions related to the COVID-19 pandemic have changed real-world practice patterns in the management of DR. This review summarizes evolving guidelines and outcomes of the treatment of DR in the setting of the pandemic.

Recent Findings

Intravitreal injections for DR have decreased significantly globally during the pandemic, ranging from approximately 30 to nearly 100% reduction, compared to corresponding timepoints in 2019. Most studies on functional outcomes show a decrease in visual acuity on delayed follow-up.

Summary

Changing practice patterns in the management of DR has led to fewer intravitreal injections and overall reduction in visual acuity on follow-up. As COVID variants emerge, it will be necessary to continue evaluating practice guidelines.

中文翻译：

---

COVID-19 对糖尿病视网膜病变监测和治疗的影响

审查目的

糖尿病视网膜病变 (DR) 是全球视力丧失的主要原因之一。尽管 DR 的筛查和早期治疗指南显着降低了疾病负担，但与 COVID-19 大流行相关的限制已经改变了 DR 管理的现实实践模式。本综述总结了在大流行背景下治疗 DR 的不断发展的指南和结果。

最近的发现

与 2019 年的相应时间点相比，全球大流行期间用于 DR 的玻璃体内注射量显着下降，下降幅度约为 30% 至近 100%。大多数关于功能结果的研究表明，延迟随访导致视力下降。

概括

DR 管理中不断变化的实践模式导致玻璃体内注射次数减少，随访时视力总体下降。随着 COVID 变种的出现，有必要继续评估实践指南。